Theragnostics strengthens leadership team with two key appointments

Chris Sterling appointed as Non-Executive Director & Radiopharmaceutical drug development expert Dr Daniel Stevens joins as Chief Medical Officer

LONDON, UK, 14 November 2019 – Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announces two strategic hires to its leadership team with the appointment of Dr Daniel Stevens as Chief Medical Officer (CMO) and Chris Stirling to the Board as Non-Executive Director.

Read more